Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 3Completed 2Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 6392Neoplasms 5365Prostatic Neoplasms 2966Carcinoma, Non-Small-Cell Lung 2709Colorectal Neoplasms 2679Lung Neoplasms 2267Multiple Myeloma 1663Lymphoma 1600Neoplasm Metastasis 1552Leukemia, Myeloid, Acute 1540Melanoma 1486Pancreatic Neoplasms 1470Ovarian Neoplasms 1423Leukemia 1389Head and Neck Neoplasms 1284Precursor Cell Lymphoblastic Leukemia-Lymphoma 1282Lymphoma, Non-Hodgkin 1231Colonic Neoplasms 1159Carcinoma, Hepatocellular 1142Stomach Neoplasms 1129Leukemia, Lymphocytic, Chronic, B-Cell 1090Brain Neoplasms 1050Rectal Neoplasms 980Lymphoma, Follicular 979Recurrence 976Uterine Cervical Neoplasms 926Glioblastoma 920Carcinoma, Renal Cell 882Lymphoma, Large B-Cell, Diffuse 853Hodgkin Disease 777

Interventions

ravulizumab 1eculizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Demyelinating Diseases × Clear all
NCT04201262 2025-10-14

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Alexion Pharmaceuticals, Inc.

Phase 3 Completed
58 enrolled 19 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

NCT02003144 2022-08-23

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Alexion Pharmaceuticals, Inc.

Phase 3 Completed
119 enrolled 17 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡